Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/97757
標題: 蘆薈大黃素透過降低Y-box致癌因子進而抑制HER-2表現在第二型人類表皮生長因子接受體過度表現的乳癌之研究
Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
作者: 馬瑞彣
Jui-Wen Ma
關鍵字: 人類第二型類上皮生長因子接受體;蘆薈大黃素;上皮細胞間質轉化;Y-box結合蛋白1;human epidermal growth factor type II;aloe-emodin;Epithelial-Mesenchymal Transition;Y-Box Binding Protein 1
引用: 1. Guaoua S, Ratbi I, Lyahyai J, El Alaoui SC, Laarabi FZ, Se ani A. Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer. Afr Health Sci. 2014; 14:468–471. 
 2. Lee HJ, Park IA, Song IH, Kim SB, Jung KH, Ahn JH, Ahn SH, Kim HH, Gong G. Comparison of pathologic response evaluation systems after anthracycline with/without taxane- based neoadjuvant chemotherapy among different subtypes of breast cancers. PloS ONE. 2015; 10:e0137885. 
 3. Adamczyk A, Niemiec J, Janecka A, Harazin-Lechowska A, Ambicka A, Grela-Wojewoda A, Domagala-Haduch M, Cedrych I, Majchrzyk K, Kruczak A, Rys J, Jakubowicz J. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting. Pol J Pathol. 2015; 66:133–141. 
 4. Christenson JL, Denny EC, Kane SE. t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib. Oncotarget. 2015. 
 5. Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, et al. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. Br J Cancer. 2015; 113: 1020–1026. 
 6. Hajighasemlou S, Alebouyeh M, Rastegar H, Manzari MT, Mirmoghtadaei M, Moayedi B, Ahmadzadeh M, Parvizpour F, Johari B, Naeini MM, Farajollahi MM. Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines. Asian Pac J Cancer Prev. 2015; 16:5977–5981. 
 7. Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Br J Cancer. 2011; 13:211. 
 8. Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med. 2013; 17:30–54. 
 9. Cammarata PR, Neelam S, Brooks MM. Inhibition of hypoxia inducible factor-1alpha downregulates the expression 
of epithelial to mesenchymal transition early marker proteins without undermining cell survival in hypoxic lens epithelial cells. Mol Vis. 2015; 21:1024–1035.
 10. Ritter A, Friemel A, Fornoff F, Adjan M, Solbach C, Yuan J, Louwen F. Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells. Oncotarget. 2015. 11. Fu P, Du F, Chen W, Yao M, Lv K, Liu Y. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1alpha downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines. Oncol Rep. 2014; 31:2561–2568. 12. Wang W, Wang HJ, Wang B, Li Y, Qin Y, Zheng LS, Zhou JS, Qu PH, Shi JH, Zhang HS. The Role of the Y Box Binding Protein 1 C-Terminal Domain in Vascular Endothelial Cell Proliferation, Apoptosis, and Angiogenesis. DNA and Cell Biology. 2015. 13. Wu Y, Wang KY, Li Z, Liu YP, Izumi H, Yamada S, Uramoto H, Nakayama Y, Ito K, Kohno K. Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature.Clin Transl Oncol. 2015; 17:152–159. 14. Fotovati A, Abu-Ali S, Wang P-S, Deleyrolle LP, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, Uchiumi T, Kuwano M, Leavitt BR, et al. YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth. Cancer Res. 2011; 71:5569–5578. 15. Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ,Wang Y. miR- 382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol Ther. 2015; 23:89–98.
 16. Davies AH, Reipas KM, Pambid MR, Berns R, Stratford AL, Fotovati A, Firmino N, Astanehe A, Hu K, Maxwell C, Mills GB, Dunn SE. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. Stem Cells (Dayton, Ohio). 2014; 32:1437–1450. 17. Hussain H, Al-Harrasi A, Al-Rawahi A, Green IR, Csuk R, Ahmed I, Shah A, Abbas G, Rehman NU, Ullah R. A fruitful decade from 2005 to 2014 for anthraquinone patents. Expert Opin Ther Pat. 2015; 25:1053–1064. 18. Zhao H, Darzynkiewicz Z. Attenuation of replication stress- induced premature cellular senescence to assess anti-aging modalities. Curr Protoc Cytom. 2014; 69:9.47.41–49.47.10. 19. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Tyrosine kinase inhibitor emodin suppresses growth of HER- 2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin. Cancer Res. 1999; 5:343–353. 20. Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu- induced cellular transformation and metastasis-associated properties. Oncogene. 1998; 16:2855–2863. 21. Ok S,Kim SM,Kim C,Nam D,Shim BS,Kim SH, Ahn KS, Choi SH, Ahn KS. Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4. Immunopharmacology and Immunotoxicology. 2012; 34:768–778. 22. Venturutti L, Romero LV, Urtreger AJ, Chervo MF, Cordo Russo RI, Mercogliano MF, Inurrigarro G, Pereyra MG, Proietti CJ, Izzo F, Diaz Flaque MC, Sundblad V, Roa JC, et al. Stat3 regulates ErbB-2 expression and co-opts ErbB- 2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis. Oncogene. 2015. 
 23. Nishio S, Ushijima K, Yamaguchi T, Sasajima Y, Tsuda H, Kasamatsu T, Kage M, Ono M, Kuwano M, Kamura T. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer. Gynecol Oncol. 2014; 132:703–708. 
 24. Gopal SK, Greening DW, Mathias RA, Ji H, Rai A, Chen M, Zhu HJ, Simpson RJ. YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment. Oncotarget. 2015; 6:13718–13730. 25. Shiota M, Yokomizo A, Itsumi M, Uchiumi T, Tada Y, Song Y, Kashiwagi E, Masubuchi D, Naito S. Twist, Y-box-binding protein-1 promote malignant potential in bladder cancer cells. Br J Urol. 2011; 108:142–149. 
 26. He L, Che M, Hu J, Li S, Jia Z, Lou W, Li C, Yang J, Sun S, Wang H, Chen X. Twist contributes to proliferation and epithelial-to-mesenchymal transition-induced brosis by regulating YB-1 in human peritoneal mesothelial cells. Am J Pathol. 2015; 185:2181–2193. 27. LiuX, YunF, ShiL, LiZH, LuoNR, JiaYF.Rolesof Signaling Pathways in the Epithelial-Mesenchymal Transition in Cancer. APJCP. 2015; 16:6201–6206. 28. Zhang W, Zhang T, Lou Y, Yan B, Cui S, Jiang L, Han B. Placental Growth Factor Promotes Metastases of Non-Small Cell Lung Cancer Through MMP9. Cell Physiol Biochem. 2015; 37:1210–1218. 29. Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE, Bally MB. A pathway involving TWIST and YB-1 regulates suppression of Her2/neu expression through ILK inhibition. Oncogene. 2010; 29:6343–56. 
 30. Pratap UP, Sharma HR, Mohanty A, Kale P, Gopinath S, Hima L, Priyanka HP, ThyagaRajan S. Estrogen upregulates in ammatory signals through NF-kappaB, IFN-gamma, and nitric oxide via Akt/mTOR pathway in the lymph node lymphocytes of middle-aged female rats. Int Immunopharmacol. 2015. 
 31. Erdogan B, Turkmen E, Yalta TD, Usta U, Kodaz H, Hacibekiroglu I, Tanriverdi O, Uzunoglu S, Cicin I. Importance of Ki-67 in human epidermal growth factor receptor 2 positive breast cancer. J Buon. 2015; 20:730–736. 
 32. Shetty P, Bargale A, Patil BR, Mohan R, Dinesh US, Vishwanatha JK, Gai PB, Patil VS, Amsavardani TS. Cell surface interaction of annexin A2 and galectin-3 modulates 
 epidermal growth factor receptor signaling in Her-2 negative breast cancer cells. Mol Cell Biochem. 2015. 33. Chu Z, Lin H, Liang X, Huang R, Zhan Q, Jiang J, Zhou X. Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases. PloS one. 2014; 9:e111493. 34. Liu AN,Sun P,Liu JN,Ma JB,Qu HJ,Zhu H,Yu CY, Zhang LM. Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev. 2012; 13:1197–1201. 35. Patki M, Salazar M, Trumbly R, Ratnam M. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells. Biochem Bioph Res Co. 2015; 457:404–411. 36. Chun-Guang W, Jun-Qing Y, Bei-Zhong L, Dan-Ting J, Chong W, Liang Z, Dan Z, Yan W. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol. 2010; 627:33–41. 37. Zheng ZH, Hu JD, Chen YY, Lian XL, Zheng HY, Zheng J, Lin MH. [Effect of emodin on proliferation inhibition and apoptosis induction in leukemic K562 cells]. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = J Exp Hematol. 2009; 17:1434–1438. 38. Pecere T, Sarinella F, Salata C, Gatto B, Bet A, Dalla Vecchia F, Diaspro A, Carli M, Palumbo M, Palu G. Involvement of p53 in speci c anti-neuroectodermal tumor activity of aloe- emodin. Int J Cancer. 2003; 106:836–847. 39. Rassouli FB, Matin MM, Saeinasab M. Cancer stem cells in human digestive tract malignancies. Tumour Biol. 2015; 37:7–21.
 40. Zumwalt TJ, Goel A. Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. Curr Colorectal Cancer Rep. 2015; 11:125–140. 41. Hirohashi Y, Torigoe T, Tsukahara T, Kanaseki T, Kochin V, Sato N. Immune Responses to Human Cancer Stem-like Cells/Cancer-initiating Cells. Cancer Sci. 2015; 107:12–17. 42. Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, Nakopoulou L. Y-box- binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identi cation of patients at high risk for relapse. Eur J Surg Oncol. 2014; 40:289–296. 43. Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015; 6:30487–30499. 44. Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor ef cacy in castration resistant prostate cancer. Oncotarget. 2015; 6:9086–9098. 45. Cybulski M, Jarosz B, Nowakowski A, Jeleniewicz W, Kutarska E, Bednarek W, Stepulak A. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer. Anticancer Res. 2015; 35:1715–1721. 
 46. Azimi I, Beilby H, Davis FM, Marcial DL, Kenny PA, Thompson EW, Roberts-Thomson SJ, Monteith GR. Altered purinergic receptor-Ca signaling associated with hypoxia- induced epithelial-mesenchymal transition in breast cancer cells. Mol Oncol. 2015. 
 47. Yang YJ, Na HJ, Suh MJ, Ban MJ, Byeon HK, Kim WS, Kim JW, Choi EC, Kwon HJ, Chang JW, Koh YW. Hypoxia Induces Epithelial-Mesenchymal Transition in Follicular Thyroid Cancer: Involvement of Regulation of Twist by Hypoxia Inducible Factor-1alpha. Yonsei Med J. 2015; 56:1503–1514. 
 48. Nakajima T, Anayama T, Koike T, Shingyoji M, Castle L, Kimura H, Yoshino I, Yasufuku K. Endobronchial ultrasound doppler image features correlate with mRNA expression of HIF1-alpha and VEGF-C in patients with non-small-cell lung cancer. J Thorac Oncol. 2012; 7:1661–1667. 
 49. Chen J, Lan T, Zhang W, Dong L, Kang N, Zhang S, Fu M, Liu B, Liu K, Zhan Q. Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer. Cancer Res. 2015; 75:4198–4210. 
 50. Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene. 2010; 29:5135–5145. 
 51. Kim JH, Hwang YJ, Han SH, Lee YE, Kim S, Kim YJ, Cho JH, Kwon KA, Kim JH, Kim SH. Dexamethasone inhibits hypoxia-induced epithelial-mesenchymal transition in colon cancer. World J Gastroenterol. 2015; 21:9887–9899. 
 52. Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.Inhibitionof Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells. Clin Lab. 2015; 61:1043–1051. 
 53. Kumar D, Das B, Sen R, Kundu P, Manna A, Sarkar A, Chowdhury C, Chatterjee M, Das P. Andrographolide Analogue Induces Apoptosis and Autophagy Mediated Cell Death in U937 Cells by Inhibition of PI3K/Akt/mTOR Pathway. PloS ONE. 2015; 10:e0139657. 54. Lot A, Mohammadi G, Saniee L, Mousaviagdas M, Chavoshi H, Tavassoli A. Serum Level of Matrix Metalloproteinase-2 and -9 in Patients with Laryngeal Squamous Cell Carcinoma and Clinical Signi cance. Asian Paci c Journal of Cancer Prevention: APJCP. 2015; 16:6749–6751. 55. Chou YC, Chang MY, Wang MJ, Yu FS, Liu HC, Harnod T, Hung CH, Lee HT, Chung JG. PEITC inhibits human brain glioblastoma GBM 8401 cell migration and invasion through the inhibition of uPA, Rho A, and Ras with inhibition of MMP-2, -7 and -9 gene expression. Oncol Rep. 2015; 34:2489–2496. 56. Jou YJ, Chen CJ, Liu YC, Way TD, Lai CH, Hua CH, Wang CY, Huang SH, Kao JY, Lin CW. Quantitative phosphoproteomic analysis reveals gamma-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation. Proteomics. 2015; 15:3296–3309. 57. Lin YC, Lin JC, Hung CM, Chen Y, Liu LC, Chang TC, Kao JY, Ho CT, Way TD. Osthole inhibits insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells. J Agric Food Chem. 2014; 62: 5061–5071. 58. Way TD, Huang JT, Chou CH, Huang CH, Yang MH, Ho CT. Emodin represses TWIST1-induced epithelial- mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the beta-catenin and Akt pathways. Eur J Cancer. 2014; 50:366–378.
摘要: 
乳癌為國人女性死因第四名,目前乳癌治療依據患者雌激素接受體(Estrogen Receptor, ER)、黄體素接受體(Progesterone Receptor, PR)及人類第二型類上皮生長因子接受體(Human Epidermal Growth Factor Receptor Type-2, HER-2)等腫瘤標記進行個人化醫療。乳腺癌細胞大量表現人類表皮生長因子受體2(HER-2)往往更具攻擊性、高轉移性及耐藥性。過去文獻指出,大黃素(emodin)是大黃植物(Rheum palmatum L.)根中的主要化合物,具有顯著抑制HER-2之表現量。本研究主旨乃在於比較大黃素類似物,大黃素(emodin)、蘆薈大黃素(aloe-emodin; AE)及大黃酸(rhein)對於抑制HER-2表現量的效果。研究證實,AE處理HER-2過度表現之乳腺癌細胞株,具有最顯著抑制HER-2蛋白表現量。有趣的是,AE抑制HER-2蛋白的表現量,主要是透過降低致癌蛋白YB-1所造成,並且在AE處理後,降低了細胞遷移和侵襲的能力。結果也表明,AE抑制癌細胞轉移蛋白Twist及vimentin的表現量,並證實AE主要透過抑制ILK / AKT / mTOR信息路徑,進而降低YB-1的表現量。體內研究證實,裸鼠誘導人類HER-2過度表達之乳腺癌腫瘤,經由AE處理後可顯著性的抑制腫瘤生長。這些研究結果可提供AE作為未來策略性治療HER-2過度表現之乳腺癌患者的用藥選擇之一。

Breast cancer is the fourth leading cause of death of female in Taiwan, The current treatment of patients with breast cancer target estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor type II (HER-2) receptor type and other tumor markers for personalized medicine. Human epidermal growth factor receptor-2 (HER-2)-positive breast cancer tends to be aggressive, highly metastatic, and drug resistant and spreads rapidly. Studies have indicated that emodin inhibits HER-2 expression. This study compared the HER- 2-inhibitory effects of two compounds extracted from rhubarb roots: aloe-emodin (AE) and rhein. Our results indicated that AE exerted the most potent inhibitory effect on HER-2 expression. Treatment of HER-2-overexpressing breast cancer cells with AE reduced tumor initiation, cell migration, and cell invasion. AE was able to suppress YB-1 expression, further suppressing downstream HER-2 expression. AE suppressed YB-1 expression through the inhibition of Twist in HER-2-overexpressing breast cancer cells. Our data also found that AE inhibited cancer metastasis and cancer stem cells through the inhibition of EMT. Interestingly, AE suppressed YB-1 expression through the downregulation of the intracellular integrin-linked kinase (ILK)/protein kinase B (Akt)/mTOR signaling pathway in HER-2-overexpressing breast cancer cells. In vivo study showed the positive result of antitumor activity of AE in nude mice injected with human HER-2-overexpressing breast cancer cells. These bindings suggest the possible application of AE in the treatment of HER-2-positive breast cancer.
URI: http://hdl.handle.net/11455/97757
Rights: 同意授權瀏覽/列印電子全文服務,2021-08-17起公開。
Appears in Collections:生物化學研究所

Files in This Item:
File SizeFormat Existing users please Login
nchu-107-8102058001-1.pdf2.77 MBAdobe PDFThis file is only available in the university internal network    Request a copy
Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.